Zidovudine Tablets IP 300 mg Manufacturer in India – Healthy Life Pharma Pvt. Ltd.

Zidovudine Tablets IP 300 mg | Manufacturer
Product image for Zidovudine Tablets IP 300 mg Manufacturer; contract manufacturing, oem & quality control.
Product Information
| Generic Name | Zidovudine |
|---|---|
| Manufacturer | Healthy Life Pharma Pvt. Ltd. |
| HSN Code | 30049099 |
| Pharmacopoeia | IP |
| Product Type | Tablet |
| Category | Antiviral drugs |
| Subcategory | Antiviral drugs |
| Active Ingredient | Zidovudine |
| Strength | 300 mg |
| Dosage Form | Tablet |
| Pack Size | 10 x 10 Tablets / Box (Alu-Alu / Blister) |
| Route of Administration | Oral |
| Prescription Required | Yes |
| Therapeutic Category | Antiviral drugs |
Medicine Details & Safety
| Short Description | Healthy Life Pharma invites contract and third-party manufacturing enquiries for Zidovudine Tablets IP 300 mg from pharmaceutical marketing companies, institutional buyers and brand owners. Production specifications, batch size and packaging are agreed against the approved product dossier and purchase requirements. | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Approved Uses / Indications | 1. Treatment of initial and recurrent mucocutaneous and genital Herpes Simplex (HSV-1, HSV-2) outbreaks. 2. Management of Herpes Zoster (shingles), Varicella (chickenpox), and suppression of recurrent viral infections. | ||||||||||||||||||||||||
| Full Description | Healthy Life Pharma invites contract and third-party manufacturing enquiries for Zidovudine Tablets IP 300 mg from pharmaceutical marketing companies, institutional buyers and brand owners. Production specifications, batch size and packaging are agreed against the approved product dossier and purchase requirements. Product technical specifications
Product technical specifications
Manufacturing capabilities and infrastructureFor Zidovudine Tablets IP 300 mg, assess the approved formulation process, equipment suitability, batch scale and in-process controls for the Tablet presentation. Confirm environmental requirements and validated process before production.Quality control and assuranceRequest the approved finished-product specification for Zidovudine Tablets IP 300 mg, including applicable identity, assay, uniformity and performance tests for the Tablet presentation. Confirm analytical methods, acceptance criteria and batch release documentation, including COA availability.Primary and secondary packagingThe catalogue pack for Zidovudine Tablets IP 300 mg is 10 x 10 Tablets / Box (Alu-Alu / Blister). Confirm primary packaging compatibility, stability evidence, artwork, batch coding and leaflet requirements against the approved specification.Contract manufacturing and private labelSubmit the target market, strength, pharmacopoeial specification, forecast volume and brand artwork. Agree feasibility, batch size, quality agreement, production schedule and release criteria before execution. | ||||||||||||||||||||||||
| Dosage Instructions | Administer orally with plenty of fluids. Initiate therapy at the earliest symptom of viral outbreak or prodromal tingling. Adhere strictly to the dosing schedule for the full recommended duration. | ||||||||||||||||||||||||
| Side Effects | Common: Nausea, headache, diarrhea, abdominal pain, fatigue, mild pruritus. Uncommon: Dizziness, fever, skin rash, arthralgia, transient elevation in bilirubin. Rare: Reversible neurological disturbances, renal tubular crystallization in dehydration. | ||||||||||||||||||||||||
| Warnings and Precautions | Adequate Hydration: Maintain abundant fluid intake throughout therapy to avoid crystalluria and renal tubular damage. Renal Dose Adjustment: Dose reduction is mandatory in renal impairment based on creatinine clearance. Early Initiation: Therapeutic efficacy is maximal when started within 24 to 72 hours of outbreak. | ||||||||||||||||||||||||
| Contraindications | 1. Known hypersensitivity to Zidovudine or chemically related nucleoside antiviral analogues. 2. Severe uncorrected dehydration. 3. Severe acute renal failure unless coordinated with hemodialysis. | ||||||||||||||||||||||||
| Drug Interactions | 1. Probenecid & Cimetidine: Compete for active renal tubular secretion, increasing antiviral AUC and elimination half-life. 2. Nephrotoxic Medications (Aminoglycosides, Cyclosporine, Amphotericin): Synergistic potential for renal injury. 3. Mycophenolate Mofetil: Co-administration elevates plasma concentrations of both compounds. |
Frequently Asked Questions
| Question | Answer |
|---|---|
| Can I request third-party manufacturing for Zidovudine Tablets IP 300 mg? | Submit your brand, quantity and packaging requirements for manufacturing feasibility review. |
| Which pharmacopoeial standard applies for Zidovudine Tablets IP 300 mg? | The source specification is IP; confirm the required standard before contracting. |
| What quality tests are applicable for Zidovudine Tablets IP 300 mg? | Request the approved finished-product specification and batch testing plan. |
| Can packaging be customized for Zidovudine Tablets IP 300 mg? | Submit artwork and pack requirements for technical and regulatory review. |
| How do I request a manufacturing quotation for Zidovudine Tablets IP 300 mg? | Provide forecast volume, target market, strength and packaging requirements. |
Related Products
✚
Zidovudine Tablets IP 300 mg ExporterView product →
✚
Zidovudine Tablets IP 300 mg SupplierView product →
✚
Adefovir Dipivoxil Tablets 10 mg ExporterView product →
✚
Adefovir Dipivoxil Tablets 10 mg ManufacturerView product →
✚
Adefovir Dipivoxil Tablets 10 mg SupplierView product →
✚
Lamivudine and Zidovudine Tablets IP 300 mg + 150 mg ExporterView product →
✚
Lamivudine and Zidovudine Tablets IP 300 mg + 150 mg ManufacturerView product →
✚
Lamivudine and Zidovudine Tablets IP 300 mg + 150 mg SupplierView product →
✚
Lamivudine Tablets IP 100 mg ExporterView product →
✚
Lamivudine Tablets IP 100 mg ManufacturerView product →
✚
Lamivudine Tablets IP 100 mg SupplierView product →
✚
Lamivudine Tablets IP 150 mg ExporterView product →
Latest Posts
✚
WHO GMP certfied Glibenclamide Metformin SR TabletsRead article →✚
WHO GMP certfied Frusemide Tablets ManufacturerRead article →✚
Folic Acid Niacinamide Tablets ManufacturerRead article →✚
WHO GMP certfied Folic Acid Tablets ManufacturerRead article →✚
WHO GMP certfied Fluconazole Tablets ManufacturerRead article →✚
WHO GMP certfied Ferrous Sulphate with folic acid TabletsRead article →✚
WHO GMP certfied iron with folic acid Tablets ManufacturerRead article →✚
WHO GMP certfied Ferrous Sulphate Tablets ManufacturerRead article →